Neuromyelitis optica spectrum disorder associated with cutaneous lupus and multidrug immunosuppressant hypersensitivity. [PDF]
Chu Han C +2 more
europepmc +1 more source
Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus. [PDF]
Martins E +13 more
europepmc +1 more source
Systemic lupus erythematosus in pregnancy: Maternal and fetal outcomes and management strategies (Review). [PDF]
Omar I, Alakhras A, Ahmad M, Mutwali S.
europepmc +1 more source
O36 HPV vaccination and cervical screening in SLE patients
Myles Lewis +9 more
doaj +1 more source
Guillain-Barré Syndrome, Subtype AMAN, Can Only Be Attributed to Lupus Erythematosus if All Infectious Causes Have Been Ruled Out [Response to Letter]. [PDF]
Sbitan L, Kanan M, Hasan HA, Hassan AM.
europepmc +1 more source
Italian Olfactory Identification Test in Systemic Lupus Erythematosus: Association of Olfactory Impairment With Chronic Damage and Anti-β<sub>2</sub>-Glycoprotein I Antibodies. [PDF]
Di Berardino M +11 more
europepmc +1 more source
Related searches:
THE COMPARISON A Multicolored (pink, brown, and white) indurated plaques in a butterfly distribution on the face of a 30-year-old woman with a darker skin tone. B Pink, elevated, indurated plaques with hypopigmentation in a butterfly distribution on the face of a 19-year-old woman with a lighter skin tone.
Candrice R, Heath, Richard P, Usatine
openaire +3 more sources
WHAT IS LUPUS? WHAT IS NOT LUPUS?
Rheumatic Disease Clinics of North America, 1993Present understanding suggests that lupus reflects a spectrum of syndromes that share many clinical, inflammatory, and immunologic features. Those patients not fulfilling criteria for systemic lupus erythematosus (SLE) do not seem to evolve frequently to classic SLE, tend to have a good prognosis, and may be managed conservatively.
R S, Panush, J M, Greer, K K, Morshedian
openaire +2 more sources
Systemic lupus erythematosus and lupus nephritis
Nature Reviews Drug Discovery, 2014The late-stage pipeline for systemic lupus erythematosus (SLE) and lupus nephritis (LN) contains biologics and small-molecule drugs for a broad range of different targets. Koutsokeras and Healy discuss their likely impact on the future SLE and LN market.
Toli, Koutsokeras, Tina, Healy
exaly +3 more sources

